Latest Response Genetics (RGDX) Headlines Respo
Post# of 9
Posted On: 03/13/2014 1:54:42 AM
Latest Response Genetics (RGDX) Headlines
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on March 20, 2014
GlobeNewswire - Wed Mar 12, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its fourth quarter and year-end financial results for 2013 and give an operational update in a press release to be issued before the market opens on Thursday, March 20, 2014. The company will host a conference call that same day at 10:00 a.m. EDT to discuss its financial results.
Response Genetics, Inc. to Offer Expanded KRAS Mutation Test to Improve Treatment Decisions for Colorectal Cancer Patients
GlobeNewswire - Mon Mar 10, 6:13AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer today announced the commercial availability of its expanded KRAS assay, a mutation detection test that provides broader coverage of KRAS mutations, including those in regions of the gene not previously examined.
2 Health Care Stocks Under $10 to Trade
at The Street - Thu Feb 20, 5:00AM CST
These health care stocks under $10 were trading higher on Wednesday. Here's how to trade them now.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 14, 5:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Response Genetics Receives Third GSK Milestone Payment
GlobeNewswire - Mon Jan 27, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has achieved its third milestone payment from GlaxoSmithKline LLC ("GSK") related to the issuance of a U.S. patent for detection of BRAF Mutations.
4 Under-$10 Health Care Stocks Moving Higher
at The Street - Fri Jan 17, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Response Genetics, Inc. Announces Contracts With Two Additional Blue Cross Blue Shield Plans
GlobeNewswire - Wed Dec 18, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has signed agreements with two new Blue Cross Blue Shield health plans.
Response Genetics, Inc. Announces Pricing of Underwritten Public Offering
GlobeNewswire - Fri Dec 13, 8:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX) (the "Company"), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, announced today it priced its previously announced underwritten public offering of 4,464,443 registered shares of its common stock, par value $0.01 per share, at a price of $1.20 per share. The Company plans to use the approximately $4,844,465 million in net proceeds of the offering for working capital and general corporate purposes. In connection with the offering, the Company has also granted the underwriter a 45-day option to purchase up to an additional 669,666 shares of common stock from the Company to cover over-allotments, if any.
Response Genetics, Inc. Announces Proposed Underwritten Public Offering
GlobeNewswire - Thu Dec 12, 3:33PM CST
Response Genetics, Inc. (Nasdaq:RGDX) (the "Company"), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, announced today it intends to offer and sell registered shares of its common stock in an underwritten public offering. The Company expects to use the net proceeds of the offering for working capital and general corporate purposes.
Response Genetics, Inc. Announces Four New Contracts With National PPO Networks
GlobeNewswire - Wed Nov 13, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has recently closed four new payor contracts with national Preferred Provider Organization ("PPO") networks. The four new provider agreements are with:
Response Genetics, Inc. Announces Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 07, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the third quarter ended September 30, 2013.
Response Genetics, Inc. to Release Third Quarter 2013 Financial Results and Host Conference Call on November 7, 2013
GlobeNewswire - Thu Oct 31, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its third quarter 2013 financial results and give an operational update in a press release to be issued before the market opens on Thursday, November 7, 2013. The company will host a conference call that same day at 10:00 a.m. EST to discuss its financial results.
Response Genetics, Inc. Announces $1.9 Million Registered Direct Offering
GlobeNewswire - Fri Sep 20, 7:45AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has entered into definitive agreements with institutional investors for the sale of 932,805 shares of its common stock in a registered direct offering at $2.05 per share, the closing price on September 19, 2013. Gross proceeds of the offering, before deducting the placement agent fee and offering expenses, are expected to be approximately $1.9 million.
OTC Daily Alert Stock Watch - Response Genetics, Inc (NASDAQ: RGDX)
WorldStockWire - Mon Sep 02, 10:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Can the Recent Uptrend Continue for Response Genetics, Inc. (RGDX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 28, 5:23AM CDT
Can the Recent Uptrend Continue for Response Genetics, Inc. (RGDX)?
Response Genetics, Inc. Acquires Proprietary FDA-Cleared and Medicare-Reimbursed Test and All Associated Assets for Difficult to Diagnose Solid Tumors
GlobeNewswire - Mon Aug 26, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced the acquisition of all of the key assets of Pathwork Diagnostics, including its FDA-cleared, Medicare-reimbursed test for the diagnosis of metastatic, poorly differentiated and undifferentiated cancer.
Response Genetics, Inc. Announces Contract With MultiPlan, Inc.
GlobeNewswire - Mon Aug 12, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has entered into an agreement with MultiPlan, Inc., the industry's most comprehensive provider of healthcare cost management solutions.
Response Genetics, Inc. Announces Second Quarter 2013 Financial Results
GlobeNewswire - Thu Aug 08, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2013.
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on March 20, 2014
GlobeNewswire - Wed Mar 12, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its fourth quarter and year-end financial results for 2013 and give an operational update in a press release to be issued before the market opens on Thursday, March 20, 2014. The company will host a conference call that same day at 10:00 a.m. EDT to discuss its financial results.
Response Genetics, Inc. to Offer Expanded KRAS Mutation Test to Improve Treatment Decisions for Colorectal Cancer Patients
GlobeNewswire - Mon Mar 10, 6:13AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer today announced the commercial availability of its expanded KRAS assay, a mutation detection test that provides broader coverage of KRAS mutations, including those in regions of the gene not previously examined.
2 Health Care Stocks Under $10 to Trade
at The Street - Thu Feb 20, 5:00AM CST
These health care stocks under $10 were trading higher on Wednesday. Here's how to trade them now.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 14, 5:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Response Genetics Receives Third GSK Milestone Payment
GlobeNewswire - Mon Jan 27, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has achieved its third milestone payment from GlaxoSmithKline LLC ("GSK") related to the issuance of a U.S. patent for detection of BRAF Mutations.
4 Under-$10 Health Care Stocks Moving Higher
at The Street - Fri Jan 17, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Response Genetics, Inc. Announces Contracts With Two Additional Blue Cross Blue Shield Plans
GlobeNewswire - Wed Dec 18, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has signed agreements with two new Blue Cross Blue Shield health plans.
Response Genetics, Inc. Announces Pricing of Underwritten Public Offering
GlobeNewswire - Fri Dec 13, 8:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX) (the "Company"), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, announced today it priced its previously announced underwritten public offering of 4,464,443 registered shares of its common stock, par value $0.01 per share, at a price of $1.20 per share. The Company plans to use the approximately $4,844,465 million in net proceeds of the offering for working capital and general corporate purposes. In connection with the offering, the Company has also granted the underwriter a 45-day option to purchase up to an additional 669,666 shares of common stock from the Company to cover over-allotments, if any.
Response Genetics, Inc. Announces Proposed Underwritten Public Offering
GlobeNewswire - Thu Dec 12, 3:33PM CST
Response Genetics, Inc. (Nasdaq:RGDX) (the "Company"), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, announced today it intends to offer and sell registered shares of its common stock in an underwritten public offering. The Company expects to use the net proceeds of the offering for working capital and general corporate purposes.
Response Genetics, Inc. Announces Four New Contracts With National PPO Networks
GlobeNewswire - Wed Nov 13, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has recently closed four new payor contracts with national Preferred Provider Organization ("PPO") networks. The four new provider agreements are with:
Response Genetics, Inc. Announces Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 07, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the third quarter ended September 30, 2013.
Response Genetics, Inc. to Release Third Quarter 2013 Financial Results and Host Conference Call on November 7, 2013
GlobeNewswire - Thu Oct 31, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its third quarter 2013 financial results and give an operational update in a press release to be issued before the market opens on Thursday, November 7, 2013. The company will host a conference call that same day at 10:00 a.m. EST to discuss its financial results.
Response Genetics, Inc. Announces $1.9 Million Registered Direct Offering
GlobeNewswire - Fri Sep 20, 7:45AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has entered into definitive agreements with institutional investors for the sale of 932,805 shares of its common stock in a registered direct offering at $2.05 per share, the closing price on September 19, 2013. Gross proceeds of the offering, before deducting the placement agent fee and offering expenses, are expected to be approximately $1.9 million.
OTC Daily Alert Stock Watch - Response Genetics, Inc (NASDAQ: RGDX)
WorldStockWire - Mon Sep 02, 10:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Can the Recent Uptrend Continue for Response Genetics, Inc. (RGDX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 28, 5:23AM CDT
Can the Recent Uptrend Continue for Response Genetics, Inc. (RGDX)?
Response Genetics, Inc. Acquires Proprietary FDA-Cleared and Medicare-Reimbursed Test and All Associated Assets for Difficult to Diagnose Solid Tumors
GlobeNewswire - Mon Aug 26, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced the acquisition of all of the key assets of Pathwork Diagnostics, including its FDA-cleared, Medicare-reimbursed test for the diagnosis of metastatic, poorly differentiated and undifferentiated cancer.
Response Genetics, Inc. Announces Contract With MultiPlan, Inc.
GlobeNewswire - Mon Aug 12, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has entered into an agreement with MultiPlan, Inc., the industry's most comprehensive provider of healthcare cost management solutions.
Response Genetics, Inc. Announces Second Quarter 2013 Financial Results
GlobeNewswire - Thu Aug 08, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2013.
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
(0)
(0)Response Genetics (RGDX) Stock Research Links
Scroll down for more posts ▼